KRYS News and Press, Krystal Biotech Inc. From 01/04/21

Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD, FRCS, FMedSci, and Jing L. Marantz, MD, PhD, MBA to its board of directors. “We are pleased t...

Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan, chairman and chief executive officer will be participating in a fireside chat at the Evercore ISI 3rd Annual HealthCONx virt...

Krystal Biotech (KRYS): Q3 GAAP EPS of -$0.49 misses by $0.04.Cash, cash equivalents and short-term investments of $286.4M.Press Release For further details see: Krystal Biotech EPS misses by $0.04

- Pivotal GEM-3 study of B-VEC in DEB expected to complete enrollment in early 2021 - Initiated the Phase 1 Study of KB301 in Facial Wrinkles and Acne Scars - Today announced additional in vivo preclinical data supporting the development of KB407 in cystic fibrosis ...

Krystal Biotech (KRYS) announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity.Senior members of Krystal’s commercial team will report directly to CEO Krish Krishnan on an interim basis. For further detai...

Krystal Biotech , Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal’s commercial team will report directly to Chief Executive Officer Krish Krishnan...

- KB301 is designed to deliver a full-length human type 3 collagen transgene via injection - The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne scars and fine wrinkles is currently enrolling Krystal Biotech , Inc. (Nasdaq:KRYS) today announced the prese...

Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chairman and chief executive officer, will be p...

PITTSBURGH, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chair...

Krystal Biotech ( KRYS +0.2% ) has initiated PEARL 1 (Phase 1) study of KB301 for acne scars and facial wrinkles. More news on: Krystal Biotech, Inc., Healthcare stocks news, Read more ...